As for DNAM-1-chimeric receptors, encouraging data have been reported on engineered T cells against melanoma (67) and the engineered-NK-92 cell line against hepatocellular cancer cells (68) and sarcoma (69). This evidence concerns the gene CD226 and sarcoma.